Skip to content

Alto Neuroscience ANRO Change in Other Assets

Change in Other Assets at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$1.48M+60.0%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$32K-94.5%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$814K-199%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
-$672K+89.9%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
-$1.28M
LBR
LB Pharmaceuticals Inc Common StockLBRX
$10.22M+12,412%

Other financials

Income statement

See full
Operating income-$27.1M-73.1%
Net income-$26.2M-73.0%
EPS (diluted)-$0.80-42.9%

Balance sheet

See full
Cash & equivalents$264.3M+63.9%
Total debt$20.9M-17.2%
Total equity$243.4M+75.0%
Total assets$276.3M+60.7%

Cash flow

See full
Operating cash flow-$27.1M-63.6%
CapEx$556.0K+2,217%
Free cash flow-$27.6M-66.7%

Valuation

See full
Market cap$887.88M+1,358%
Enterprise value$644.49M-958%

Returns & leverage

See full
Return on equity-38.9%+0.9pp
Debt / equity0.1×-0.1×
Current ratio20.5×-2.0×

Where this comes from

Reported directly by Alto Neuroscience in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alto Neuroscience's change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alto Neuroscience's change in other assets?
Alto Neuroscience (ANRO) reported change in other assets of $4.13M in Q1 2026.
How has Alto Neuroscience's change in other assets changed year-over-year?
Alto Neuroscience's change in other assets increased by 144.1% year-over-year, from $1.69M to $4.13M.
What does change in other assets mean?
Change in miscellaneous assets affecting operating cash flow.